Independent Data Monitoring Committee Recommends Resuming Enrollment of Non-Squamous NSCLC Patients in the Motesanib MO... (se competitive with its products. In ad...)

HOME >> MEDICINE >> TECHNOLOGY

Independent Data Monitoring Committee Recommends Resuming Enrollment of Non-Squamous NSCLC Patients in the Motesanib MONET1 Trial

Date:2/11/2009

se competitive with its products. In addition, while Amgen routinely obtains patents for its products and technology, the protection offered by its patents and patent applications may be challenged, invalidated or circumvented by its competitors and there can be no guarantee of Amgen's ability to obtain or maintain patent protection for its products or product candidates. Amgen cannot guarantee that it will be able to produce commercially successful products or maintain the commercial success of its existing products. Amgen's stock price may be affected by actual or perceived market opportunity, competitive position, and success or failure of its products or product candidates. Further, the discovery of significant problems with a product similar to one of Amgen's products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on Amgen's business and results of operations.

The scientific information discussed in this news release related to Amgen's product candidates is preliminary and investigative. Such product candidates are not approved by the U.S. Food and Drug Administration (FDA), and no conclusions can or should be drawn regarding the safety or effectiveness of the product candidates. Only the FDA can determine whether the product candidates are safe and effective for the use(s) being investigated. Further, the scientific information discussed in this news release relating to new indications for Amgen's products is preliminary and investigative and is not part of the labeling approved by the U.S. Food and Drug Administration (FDA) for the products. The products are not approved for the investigational use(s) discussed in this news release, and no conclusions can or should be drawn regarding the safety or effectiveness of the products for these uses. Only the FDA can determine whether the products are safe and effective for these uses. Healthcare professionals should refe
'/>"/>

SOURCE Amgen
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7
Related medicine technology :

1. Mindset Media Study Reveals Which Independent Voters Favor Obama Vs. McCain
2. Independent Analyses of the SEAS, SHARP and IMPROVE-IT Studies of Ezetimibe
3. Modigene Platform Validated in Independent Phase III Trial of CTP Technology
4. Emisphere Announces Data From Independent Clinical Study of Effects of Oral GLP-1 on Glucose and Insulin Concentrations
5. New Study Shows BENICAR(R) (olmesartan medoxomil) Reverses Blood Vessel Damage Independent of Blood Pressure Lowering
6. Soliris(R) Improved Fatigue Independent of Changes in Anemia in Patients with PNH by Controlling Hemolysis
7. Two Large, Independent Outcomes Trials Offer New Important Safety Information on Cardiovascular Effects of AVANDIA(R)
8. ASPIRE Independent Review Board Announces 10 Ways to Protect Participants Rights in Clinical Drug Trials and Optimize Results From Research
9. Promise of Vicals CMV Vaccine Noted by Independent Experts
10. Video: Major Independent Trial Demonstrates Significant Anticancer Benefit of Zometa(R) in Women With Early-Stage Breast Cancer
11. Seven Presentations by Two Independent Research Groups Highlight Advantages of Pressure Cycling Technology (PCT) at Scientific Symposia in Philadelphia, Boston, and New York City

Post Your Comments:

(Date:12/15/2009)... Bend Research Inc. announced,today that its clients ... an,excipient used in technologies developed by the firm to ... Bend Research clients may now reference ... regulatory filings with the FDA, Bend Research officials said. ... new development and know it will assist our,clients in ...

(Date:12/14/2009)... Dec. 14 BioTrends Research Group, Inc. ... a syndicated publication offering comprehensive insight into the ... based on a comparison of self-reported treatment approaches ... level data for over 1,000 RA patients who ... To be eligible for the audit, patients had ...

(Date:12/14/2009)... 14 Seven leading cancer ... US Oncology Research participated in ... the 2009 San Antonio Breast ... at the Henry B. Gonzalez ... Texas . Fifteen others presented ...

[0] Bend Research Clients May Now Reference Key Safety Document for Important Solubility Excipient [0] New Market Research Report from BioTrends Provides Insight on How Rheumatologists are Utilizing Biologic Agents in the Treatment of Rheumatoid Arthritis [0] US Oncology Research Network Participates in Seven Oral Clinical Studies Presentations and 15 Posters at 2009 San Antonio Breast Cancer Symposium

... Strativa,Pharmaceuticals, the proprietary products division of ... today announced that its development partner,Alfacell Corporation ... preliminary,statistical analysis of data from its confirmatory ... ONCONASE (ranpirnase), did not meet statistical,significance for ...

... Showed Clinically Meaningful Benefits for Patients with,Chemotherapy-Induced ... May 29 ,GlaxoSmithKline (GSK) today announced the ... U.S. Food and Drug Administration and new ... (casopitant), a novel,investigational NK-1 receptor antagonist. The ...

Other Medicine Technology:Strativa Pharmaceuticals Announces Preliminary Results from ONCONASE(R) Phase IIIb Clinical Trial 2 Strativa Pharmaceuticals Announces Preliminary Results from ONCONASE(R) Phase IIIb Clinical Trial 3 Strativa Pharmaceuticals Announces Preliminary Results from ONCONASE(R) Phase IIIb Clinical Trial 4 GlaxoSmithKline Announces New Drug Application and Phase III Results for Rezonic(TM)/Zunrisa(TM) (Casopitant) 2 GlaxoSmithKline Announces New Drug Application and Phase III Results for Rezonic(TM)/Zunrisa(TM) (Casopitant) 3 GlaxoSmithKline Announces New Drug Application and Phase III Results for Rezonic(TM)/Zunrisa(TM) (Casopitant) 4 GlaxoSmithKline Announces New Drug Application and Phase III Results for Rezonic(TM)/Zunrisa(TM) (Casopitant) 5 GlaxoSmithKline Announces New Drug Application and Phase III Results for Rezonic(TM)/Zunrisa(TM) (Casopitant) 6 GlaxoSmithKline Announces New Drug Application and Phase III Results for Rezonic(TM)/Zunrisa(TM) (Casopitant) 7 GlaxoSmithKline Announces New Drug Application and Phase III Results for Rezonic(TM)/Zunrisa(TM) (Casopitant) 8

Strativa Pharmaceuticals Announces Preliminary Results from ONCONASE(R) Phase IIIb Clinical Trial GlaxoSmithKline Announces New Drug Application and Phase III Results for Rezonic(TM)/Zunrisa(TM) (Casopitant)

(Date:12/15/2009)... CHICAGO, Dec. 15 Research shows a ... return on investment as building a culture of ... improved performance(1). According to a new white paper ... wellness solutions, the workplace represents an ideal setting ... and building and sustaining a corporate culture of ...

(Date:12/15/2009)... CHICAGO, Dec. 15 The following is being ... ,, Remarks by: Vera Rulon, MS, RHIT, CCS, ... morning, everyone and thank you joining us... ,, On ... great pleasure to introduce our next chief executive officer, ... embarked on a nationwide search for someone who we ...

(Date:12/15/2009)... midwife are generally associated with different tests and/or ... more. Women, doctors and midwives are agreed that ... sexual health, reveals a thesis from the Sahlgrenska ... Many young women see sex as a problem, ... answered questions about their sex lives, their relationships ...

(Date:12/15/2009)... Spanish scientists have found the first potential immunological clue ... by the pandemic H1N1 virus. , The study ... patients, 15 outpatients and 15 control subjects in 10 ... and August 2009. Researchers from the Hospital Clinico Universitario ... found high levels of a molecule called interleukin 17 ...

(Date:12/15/2009)... people really benefit from their looks, and in what ... Georgia and the University of Kansas found that yes; ... and therefore an increased sense of psychological well-being. This ... spend billions of dollars each year trying to become ... issue of Personal Relationships , also determines that ...

Breaking Medicine News(10 mins):Health News:Optimizing Corporate Culture is Critical to the Success of Wellness Programs 2 Health News:Dowling Press Availability Tuesday, December 15, 2009 / 10:00 a.m. CST 2 Health News:More about sex and relationships needed at gynecological visits 2 Health News:First immunological clue to why some H1N1 patients get very ill or die 2 Health News:The importance of attractiveness depends on where you live 2

[0] Optimizing Corporate Culture is Critical to the Success of Wellness Programs [0] Dowling Press Availability Tuesday, December 15, 2009 / 10:00 a.m. CST [0] More about sex and relationships needed at gynecological visits [0] First immunological clue to why some H1N1 patients get very ill or die [0] The importance of attractiveness depends on where you live

... Inc. (NYSE: ARE ) today announced the Company ... Monday, February 9, 2009, at 3:00 p.m. Eastern Time (ET), ... results for the fourth quarter and year ended December 31, ... before the market opens on Monday, February 9, 2009. , ...

... 2 Walden University,s M.S. in ... Council for Accreditation,of Counseling and Related Educational Programs ... for Higher Education,Accreditation that accredits counselor preparation master,s ... education institution that offers a,CACREP-accredited M.S. degree in ...

... the formation of fibroblasts during development also promotes their ... et al. in the February 9, 2009 issue of ... conversion of epithelial cells into fibroblast-like mesenchymal cells is ... The transcription factor Snail1 induces this conversion (known as ...

... Pharmacy Retail Level, Kidz-Med Thermofocus 5-in-1 Debuts on "Fox ... Resources (Pink Sheets: ASFX) today announced that pharmacy retail ... of 2008 compared to the 4th quarter of 2007. ... the economic recession, since implementing particular offline and online ...

... Availity, LLC, a leading health,information network, today ... of medical and behavioral health management software, ... transactions. Health care,providers with MedEZ software can ... Information Network. The partnership provides MedEZ,customers with ...

... @Heart Campaign Encourages the 44 Million Women Living with or ... Heart Health -WASHINGTON, Feb. 2 Heart disease is the ... still not receiving the same in-hospital treatment that men do ... more likely to die.(ii) In an effort to address ...

Other Medicine News:Health News:Walden University's M.S. in Mental Health Counseling Program Receives CACREP Accreditation 2 Health News:Walden University's M.S. in Mental Health Counseling Program Receives CACREP Accreditation 3 Health News:Fibroblasts invade at a snail's pace 2 Health News:Q4 2008 Sales Increase for Health and Safety Products Company 2 Health News:Q4 2008 Sales Increase for Health and Safety Products Company 3 Health News:Availity Partners With MedEZ 2 Health News:Bayer Healthcare and WomenHeart Launch Strong @Heart Campaign 2 Health News:Bayer Healthcare and WomenHeart Launch Strong @Heart Campaign 3 Health News:Bayer Healthcare and WomenHeart Launch Strong @Heart Campaign 4 Health News:Bayer Healthcare and WomenHeart Launch Strong @Heart Campaign 5

Alexandria Real Estate Equities, Inc. to Hold Its Fourth Quarter and Year End 2008 Operating and Financial Results Conference Call and Web Cast on February 9, 2009 Walden University's M.S. in Mental Health Counseling Program Receives CACREP Accreditation Fibroblasts invade at a snail's pace Q4 2008 Sales Increase for Health and Safety Products Company Availity Partners With MedEZ Bayer Healthcare and WomenHeart Launch Strong @Heart Campaign

Inquire...

VACUETTE paediatric tubes have decreased sample volumes and are ideal for small childrens' veins and geriatric patients....

... either EDTA K2 or EDTA K3 ... and therefore blocks the coagulation cascade. ... EDTA anticoagulated blood sample are stable ... tubes are for the examination of ...

Glass Whole Blood Tube with K3EDTA...

Medicine Products:

MONOJECT CLEAR LABEL Lavender Stopper (for SYSMEX Analyzer)VACUETTE Paediatric EDTA Tubes - Non-ridged (pull cap)VACUETTE EDTA tubes - Ridged (safety screw cap)Glass Whole Blood Tube with K3EDTA

Independent Data Monitoring Committee Recommends Resuming Enrollment of Non-Squamous NSCLC Patients in the Motesanib MO...(se competitive with its products. In ad...),Health